Superworth

Acadia Pharmaceuticals PE ratio ACAD

Share price divided by earnings per share over the last twelve months, since 2024.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
12.3×
Sep 2026
2-year median
16.6×
2-year range
10.2× to 92.1×
Peer median
24.3×

Acadia Pharmaceuticals' PE ratio is not a meaningful number today: net income over the last twelve months was more than twice operating income, so most of it came from below the operating line (a gain on a sale, debt written off, a tax benefit, investment income) and the low PE on it says nothing about the business.

It was last meaningful in Sep 2026, at 12.3×.

On the days it had one over the last 2 years, its median was 16.6×, from 10.2× in May 2026 to 92.1× in Aug 2024.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far12.3×10.2×17.3×
202517.8×10.7×25.7×
202421.7×20.9×92.1×

Against its peers

Companies in Drug Manufacturers - General nearest Acadia Pharmaceuticals' size, closest first, today.

CompanyPE ratio
ACADAcadia Pharmaceuticalsn/m
OGNOrganon17.9×
LQDALiquidia30.7×
ARQTArcutis Biotherapeutics142×
INDVIndivior Pharmaceuticals12.4×
NRIXNurix Therapeutics11.0×
PBHPrestige Consumer Healthcare13.4×
HRMYHarmony Biosciences11.7×
KNSAKiniksa Pharmaceuticals International79.1×
LGNDLigand Pharmaceuticals32.3×
AMRXAmneal Pharmaceuticals41.6×
Peer median24.3×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Acadia Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.